CN109423516A - Pass through the kit of molecular marker analyte detection Radiotherapy for Pituitary Adenoma sensibility or repellence - Google Patents
Pass through the kit of molecular marker analyte detection Radiotherapy for Pituitary Adenoma sensibility or repellence Download PDFInfo
- Publication number
- CN109423516A CN109423516A CN201710744118.9A CN201710744118A CN109423516A CN 109423516 A CN109423516 A CN 109423516A CN 201710744118 A CN201710744118 A CN 201710744118A CN 109423516 A CN109423516 A CN 109423516A
- Authority
- CN
- China
- Prior art keywords
- radiotherapy
- molecular marker
- pituitary adenoma
- drd2
- mgmt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Microbiology (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
Abstract
This disclosure relates to which a kind of reagent of the expression of detection molecules marker is preparing the purposes in the product for detecting Radiotherapy for Pituitary Adenoma sensibility or repellence, a kind of kit for monitoring Radiotherapy for Pituitary Adenoma sensibility or repellence and a kind of molecular marker for detecting Radiotherapy for Pituitary Adenoma sensibility or repellence combine.The disclosure can detect treatment object to the sensibility or repellence of Radiotherapy for Pituitary Adenoma by the expression quantity of detection molecules marker, analyse whether that there are radiotherapy resistances, to receive the effect after radiotherapy for prediction patient and clinic diagnosis is instructed to provide effective foundation.
Description
Technical field
The present invention relates to pituitary adenoma molecular marker fields, and in particular, to molecular marker is radiated in pituitary adenoma
Purposes in therapeutic sensitivity or repellence and pass through molecular marker analyte detection Radiotherapy for Pituitary Adenoma sensibility or repellence
Kit.
Background technique
Pituitary adenoma is nervous system kinds of tumor, accounts for about the 10%-25% of intracranial tumors.Pituitary adenoma can be divided into function
Type adenoma and nonfunctioning adenoma.Functional form hypophysoma, which is called, does secreting type hypophysoma, is divided into prolactin pituitary, growth hormone gland
Tumor, corticotropin adenoma, thyrotroph adenoma etc., such adenoma shows as excessive secretion pituitrin, such as grows
Hormone, prolactin(PRL etc..Partial function type hypophysoma has the biological characteristics of invasion, easily remains and recurs after operation.Nonfunctional
Type pituitary adenoma is one of the most common type brain tumor in hypophysoma, although it is benign tumour, its harm is very big and pole
It is easy to recur, patient's vision can be damaged, sudden blindness and influence endocrine function is caused to cause patient infertile, serious person
It may also lead to life danger.Treatment means clinically are mainly based on operation excision, but since nonfunctioning pituitary adenoma exists
The early stage of development lacks clinical symptoms, is just found until being grown to macroadenoma, and at this moment hypophysoma has invaded or around surrounding group
Growth is knitted, operation is difficult to cut off and easily recur completely.So either for functional form pituitary adenoma still for idle
Adjuvant treatment after energy type resection of pituitary adenoma is all necessary.Adjuvant treatment includes radiotherapy (such as: gamma knife)
And chemotherapy, but found from current case research, some patientss do not obtain good effect after Gamma knife treatment,
Pituitary adenoma does not reduce, or increases instead over time, these symptoms all imply using gamma knife into
When row radiotherapy, radiotherapy resistance is produced.Precisely the marrow of medical treatment formulates personalized treatment aiming at the patient of different situations
Scheme has the case of radiotherapy sensitivity in functional form and nonfunctioning pituitary adenoma, the case for also having radiotherapy to resist.
Currently, the molecular marker for identifying and predicting Radiotherapy for Pituitary Adenoma sensitivity, domestic and foreign literature is not
Report, so being badly in need of the discovery of such marker on clinical treatment preferably to serve the radiotherapy of pituitary adenoma.
Summary of the invention
Purpose of this disclosure is to provide one kind to be related to molecular marker in Radiotherapy for Pituitary Adenoma sensibility or repellence
In purposes and kit by molecular marker analyte detection Radiotherapy for Pituitary Adenoma sensibility or repellence.
To achieve the goals above, disclosure first aspect: the reagent for providing a kind of quantitative detection of molecules marker is being made
The purposes being ready for use in the product of detection Radiotherapy for Pituitary Adenoma sensibility or repellence, wherein the molecular marker is
Selected from least one of EGFR, DRD2, SFRP2, MGMT, VCAM, FSCN, P21, phosphorylation SMAD3 and phosphorylated CREB 1/2.
Optionally, the molecular marker is EGFR, DRD2, SFRP2, MGMT, VCAM, FSCN, P21, phosphorylation SMAD3
With phosphorylated CREB 1/2.
Optionally, quantitative detection of molecules marker through the following steps that carry out:
1) pituitary adenoma tissues sample is obtained；And
2) expression quantity of molecular marker in sample is determined.
Optionally, the method for step 2) is selected from PCR method, western blot, North-Western trace, immuno absorbence
Measuring method, Antibody microarray, micro-array tissue, immunoprecipitation, in situ hybridization and other immunohistochemistry technologies, radio-immunity
Measuring method, immunoradiometry and immunoenzymometric.
Disclosure second aspect: it provides a kind of for monitoring the reagent of Radiotherapy for Pituitary Adenoma sensibility or repellence
Box, wherein the kit includes the reagent of quantitative detection of molecules marker, the molecular marker be selected from EGFR, DRD2,
At least one of SFRP2, MGMT, VCAM, FSCN, P21, phosphorylation SMAD3 and phosphorylated CREB 1/2.
Optionally, the molecular marker is EGFR, DRD2, SFRP2, MGMT, VCAM, FSCN, P21, phosphorylation SMAD3
With phosphorylated CREB 1/2.
Optionally, the reagent is PCR reagent, western blot, North-Western trace, immunosorbent assay
Method, Antibody microarray, micro-array tissue, immunoprecipitation, in situ hybridization and other immunohistochemistry technologies, radiommunoassay
The detection reagent of method, immunoradiometry, immunoenzymometric.
The disclosure third aspect: it provides a kind of for detecting the molecule mark of Radiotherapy for Pituitary Adenoma sensibility or repellence
Will object combination, wherein molecular marker combination includes EGFR, DRD2, SFRP2, MGMT, VCAM, FSCN, P21, phosphorylation
At least two in SMAD3 and phosphorylated CREB 1/2.
Optionally, the molecular marker combination is by EGFR, DRD2, SFRP2, MGMT, VCAM, FSCN, P21, phosphorylation
SMAD3 and phosphorylated CREB 1/2 form.
Through the above technical solutions, disclosure application immunohistochemical method has detected pituitary gland after radiotherapy
The expression of EGFR, DRD2, SFRP2, MGMT, VCAM, FSCN, P21, phosphorylation SMAD3 and phosphorylated CREB 1/2 in tumor tissue are shied
It is found in the patient resisted there are radiotherapy oddly, EGFR, DRD2, SFRP2, MGMT, VCAM, FSCN, P21, phosphorylation
The expression quantity of SMAD3 and phosphorylated CREB 1/2 is apparently higher than radiotherapy sensitivity group.The disclosure find for the first time EGFR, DRD2,
SFRP2, MGMT, VCAM, FSCN, P21, phosphorylation SMAD3 and phosphorylated CREB 1/2 can be used as prediction pituitary adenoma radiation and control
The molecular marker for treating sensibility or repellence, provides new reference frame and therapy target for the treatment of pituitary adenoma, provides
With targetedly therapeutic scheme.
Other feature and advantage of the disclosure will the following detailed description will be given in the detailed implementation section.
Specific embodiment
The specific embodiment of the disclosure is described in detail below.It should be understood that described herein specific
Embodiment is only used for describing and explaining the disclosure, is not limited to the disclosure.
Disclosure first aspect: the reagent for providing a kind of quantitative detection of molecules marker is being prepared for detecting pituitary adenoma
Purposes in radiotherapeutic response or the product of repellence, wherein the molecular marker be selected from EGFR, DRD2,
At least one of SFRP2, MGMT, VCAM, FSCN, P21, phosphorylation SMAD3 and phosphorylated CREB 1/2.
In a kind of particularly preferred embodiment of the disclosure, the molecular marker be EGFR, DRD2, SFRP2,
MGMT, VCAM, FSCN, P21, phosphorylation SMAD3 and phosphorylated CREB 1/2.
The details of the molecular marker are as shown in table 1:
Table 1
Further, quantitative detection of molecules marker through the following steps that carry out:
1) pituitary adenoma tissues sample is obtained；And
2) expression quantity of molecular marker in sample is determined.
Wherein, step 2) really in random sample product the expression quantity method of molecular marker be selected from PCR method, western blot,
North-Western trace, immmunosorbent assay, Antibody microarray, micro-array tissue, immunoprecipitation, in situ hybridization and its
His immunohistochemistry technology, radioimmunoassay, immunoradiometry and immunoenzymometric.Wherein, EGFR,
The quantitative detection of DRD2, SFRP2, MGMT, VCAM, FSCN and P21 can be the quantitative detection on protein level, be also possible to
Quantitative detection in mRNA level in-site.Phosphorylation SMAD3 and phosphorylated CREB 1/2 can be the quantitative inspection in phosphorylated protein level
It surveys.
Disclosure second aspect: it provides a kind of for monitoring the reagent of Radiotherapy for Pituitary Adenoma sensibility or repellence
Box, wherein the kit includes the reagent of quantitative detection of molecules marker, the molecular marker be selected from EGFR, DRD2,
At least one of SFRP2, MGMT, VCAM, FSCN, P21, phosphorylation SMAD3 and phosphorylated CREB 1/2.
In a kind of particularly preferred embodiment of the disclosure, the molecular marker be EGFR, DRD2, SFRP2,
MGMT, VCAM, FSCN, P21, phosphorylation SMAD3 and phosphorylated CREB 1/2.
Further, the reagent is PCR reagent, western blot, North-Western trace, immunosorbent assay
Method, Antibody microarray, micro-array tissue, immunoprecipitation, in situ hybridization and other immunohistochemistry technologies, radiommunoassay
The detection reagent of method, immunoradiometry, immunoenzymometric.
When using kit of the present invention, the expression quantity of interpretation molecular marker.
When timing on EGFR expression quantity, indication is insensitive to radiotherapy, and there are radiotherapy resistances.
When timing under EGFR expression quantity, indication is sensitive to radiotherapy, and there is no radiotherapies to resist.
When timing on DRD2 expression quantity, indication is insensitive to radiotherapy, and there are radiotherapy resistances.
When timing under DRD2 expression quantity, indication is sensitive to radiotherapy, and there is no radiotherapies to resist.
When timing on SFRP2 expression quantity, indication is insensitive to radiotherapy, and there are radiotherapy resistances.
When timing under SFRP2 expression quantity, indication is sensitive to radiotherapy, and there is no radiotherapies to resist.
When timing on MGMT expression quantity, indication is insensitive to radiotherapy, and there are radiotherapy resistances.
When timing under MGMT expression quantity, indication is sensitive to radiotherapy, and there is no radiotherapies to resist.
When timing on VCAM expression quantity, indication is insensitive to radiotherapy, and there are radiotherapy resistances.
When timing under VCAM expression quantity, indication is sensitive to radiotherapy, and there is no radiotherapies to resist.
When timing on FSCN expression quantity, indication is insensitive to radiotherapy, and there are radiotherapy resistances.
When timing under FSCN expression quantity, indication is sensitive to radiotherapy, and there is no radiotherapies to resist.
When timing on P21 expression quantity, indication is insensitive to radiotherapy, and there are radiotherapy resistances.
When timing under P21 expression quantity, indication is sensitive to radiotherapy, and there is no radiotherapies to resist.
When timing on phosphorylation SMAD3 expression quantity, indication is insensitive to radiotherapy, and there are radiotherapy resistances.
When timing under phosphorylation SMAD3 expression quantity, indication is sensitive to radiotherapy, and there is no radiotherapies to resist.
When timing on 1/2 expression quantity of phosphorylated CREB, indication is insensitive to radiotherapy, and there are radiotherapy resistances.
When timing under 1/2 expression quantity of phosphorylated CREB, indication is sensitive to radiotherapy, and there is no radiotherapies to resist.
The disclosure third aspect: it provides a kind of for detecting the molecule mark of Radiotherapy for Pituitary Adenoma sensibility or repellence
Will object combination, wherein molecular marker combination includes EGFR, DRD2, SFRP2, MGMT, VCAM, FSCN, P21, phosphorylation
At least two in SMAD3 and phosphorylated CREB 1/2.
In a kind of particularly preferred embodiment of the disclosure, molecular marker combination by EGFR, DRD2,
SFRP2, MGMT, VCAM, FSCN, P21, phosphorylation SMAD3 and phosphorylated CREB 1/2 form.
And the table of EGFR, DRD2, SFRP2, MGMT, VCAM, FSCN, P21, phosphorylation SMAD3 and phosphorylated CREB 1/2
It is raised up to amount, indication is insensitive to radiotherapy, and there are radiotherapy resistances.EGFR,DRD2,SFRP2,MGMT,VCAM,
Timing under the expression quantity of FSCN, P21, phosphorylation SMAD3 and phosphorylated CREB 1/2, indication is sensitive to radiotherapy, and there is no put
Treatment is penetrated to resist.
Purposes, kit and molecular marker combination provided by the present invention can be applied to through detection molecules mark
The expression quantity of object detects treatment object to the sensibility or repellence of Radiotherapy for Pituitary Adenoma, analyses whether that there is radiation controls
It treats and resists, to receive the effect after radiotherapy for prediction patient and clinic diagnosis is instructed to provide effective foundation.
Detailed description of the preferred embodiments below.It should be understood that described herein specific
Embodiment is merely to illustrate and explain the present invention, and is not intended to restrict the invention.
Embodiment 1
The preparation of sample:
(1) taking hypophysoma sample, (hypophysoma sample comes from biopsy or operation, and sample receives radiation before carrying out this experiment
Treatment, the center dosage 26-33Gy of gamma knife, periphery dosage 13-16Gy, time are 50-60 minutes.) carry out wax embedding:
70%, 80%, 90%, 95%, 95% ethyl alcohol is respectively placed 1 hour；100% ethyl alcohol is placed 30 minutes, is repeated once；Dimethylbenzene is put
It sets 20 minutes, is repeated once；It is dipped in wax liquor 30 minutes, is repeated twice.
(2) sample wax stone is sliced, thickness about 5um.
(3) slice is placed in 56-60 degree oven about 0.5-1 hours.
Immunohistochemical staining
(1) using coming card active immunity group instrument (model LEICA BOND III), detection albumen mark on computers is corresponded to
Label, while the operating condition and antibody bottle number of the protein antibodies of operation detection on computers.Phosphorylation SMAD3 (article No.:
Ab118825 operating condition): antibody concentration 1:800, acid are repaired 3 minutes, and primary antibody is incubated for 15 minutes；Phosphorylated CREB 1/2
The operating condition of (article No.: ab32538): this antibody is working concentration 1:100, and acid is repaired 10 minutes, and primary antibody is incubated for 15 minutes；
The operating condition of EGFR (article No.: ab40815): antibody concentration 1:800, acid are repaired 20 minutes, and primary antibody is incubated for 15 minutes；
The operating condition of SFRP2 (article No.: ab92667): antibody concentration 1:400, acid are repaired 5 minutes, and primary antibody is incubated for 30 minutes；DRD2
The operating condition of (article No.: NLS1403): antibody concentration 3ug/ml, alkali are repaired 15 minutes, and primary antibody is incubated for 15 minutes；VCAM (goods
Number: operating condition ab98954): antibody concentration 1:800, acid are repaired 10 minutes, and primary antibody is incubated for 15 minutes；FSCN (article No.:
Ab126772 operating condition): antibody concentration 1:500, alkali are repaired 20 minutes, and primary antibody is incubated for 15 minutes, MGMT (ZM-0461)
Operating condition: working solution, acid are repaired 20 minutes, and primary antibody is incubated for 15 minutes, the operating condition of P21 (article No.: ab80633): anti-
Bulk concentration is 1:400, and acid is repaired 5 minutes, and primary antibody is incubated for 15 minutes.The DAB and haematoxylin dyed above is to come card group chemical industry
Make liquid, dyeing time is 2 minutes；In addition to DRD2 is purchased from company, Zhong Shan Golden Bridge purchased from NOVUS company MGMT, remaining primary antibody is purchased from
Abcam company；Secondary antibody is purchased from Lai Ka Reagent Company.
(2) printed label is attached on slide, slide placement is come on card active immunity group instrument, start to dye journey
Sequence.
(3) it takes out piece to place in slide elution shelf, wash by water 2-5 minutes under tap water.
(4) frame and piece will entirely be eluted together successively from 75%, 75%, 85%, 85%, 95%, 95% ethyl alcohol, diformazan
Benzene, dimethylbenzene are put into, and every kind of liquid is placed 1 minute, and whole process is got off 8-10 minutes.
(5) mounting.
Result judgement:
It is scanned using card automatic scanner is come, is analyzed after scanning, provided for every an example hypophysoma sample
The interpretation of EGFR, DRD2, SFRP2, MGMT, VCAM, FSCN, 1/2 expression quantity of P21, phosphorylation SMAD3 and phosphorylated CREB.
Observation is tracked to the patient for obtaining every an example hypophysoma sample, is carried out according to follow-up MRI tumor volume change
Judgement, the radiotherapeutic response determined above of tumor mass reduction 20%.
According to document Stereotactic radiosurgery for acromegaly (Lee CC, Vance ML, Xu
Z,Yen CP,Schlesinger D,Dodson B,Sheehan J.J Clin Endocrinol Metab.2014 Apr；99
(4): 2014 Jan 28 of 1273-81.doi:10.1210/jc.2013-3743.Epub the Statistic analysis method in) is right
EGFR, DRD2, SFRP2, MGMT, VCAM, FSCN, P21, phosphorylation SMAD3 and 1/2 quantitative values of phosphorylated CREB are in radiotherapy
Sensibility does statistical analysis (total sample number is 89), obtains statistical result as shown in Table 2.
In table 2, single factor test statistical analysis P value and multifactor statistical analysis P value are respectively less than 0.05, it was demonstrated that EGFR, DRD2,
SFRP2, MGMT, VCAM, FSCN, P21, phosphorylation SMAD3 and 1/2 quantitative values of phosphorylated CREB respectively with radiotherapeutic response
Or exist between repellence with the correlation in statistical significance；Related proportional numerical value (Ratio) is the numerical value greater than 1, card
Bright EGFR, DRD2, SFRP2, MGMT, VCAM, FSCN, P21, phosphorylation SMAD3 and 1/2 quantitative values of phosphorylated CREB and radiation are controlled
It treats to exist between repellence and be positively correlated, related proportional numerical value (Ratio) is bigger, and correlation is higher.
Therefore, in EGFR, DRD2, SFRP2, MGMT, VCAM, FSCN, P21, phosphorylation SMAD3 and phosphorylated CREB 1/2
It individually or all may be used as the molecular marker of detection Radiotherapy for Pituitary Adenoma sensibility or repellence.Quantitative detection
It is independent or whole in EGFR, DRD2, SFRP2, MGMT, VCAM, FSCN, P21, phosphorylation SMAD3 and phosphorylated CREB 1/2
Reagent may be used as the product of detection Radiotherapy for Pituitary Adenoma sensibility or repellence.
Table 2
The preferred embodiment of the disclosure is described in detail above, still, during the disclosure is not limited to the above embodiment
Detail a variety of simple variants can be carried out to the technical solution of the disclosure in the range of the technology design of the disclosure, this
A little simple variants belong to the protection scope of the disclosure.
It is further to note that specific technical features described in the above specific embodiments, in not lance
In the case where shield, can be combined in any appropriate way, in order to avoid unnecessary repetition, the disclosure to it is various can
No further explanation will be given for the combination of energy.
In addition, any combination can also be carried out between a variety of different embodiments of the disclosure, as long as it is without prejudice to originally
Disclosed thought, it should also be regarded as the disclosure of the present invention.
Claims (9)
1. a kind of reagent of quantitative detection of molecules marker is in preparation for detecting Radiotherapy for Pituitary Adenoma sensibility or resistance
Property product in purposes, wherein the molecular marker be selected from EGFR, DRD2, SFRP2, MGMT, VCAM, FSCN, P21,
At least one of phosphorylation SMAD3 and phosphorylated CREB 1/2.
2. purposes according to claim 1, wherein the molecular marker be EGFR, DRD2, SFRP2, MGMT, VCAM,
FSCN, P21, phosphorylation SMAD3 and phosphorylated CREB 1/2.
3. purposes according to claim 1 or 2, wherein quantitative detection of molecules marker through the following steps that carry out:
1) pituitary adenoma tissues sample is obtained；And
2) expression quantity of molecular marker in sample is determined.
4. purposes according to claim 3, wherein the method for step 2) is selected from PCR method, western blot, North-
Western blot, immmunosorbent assay, Antibody microarray, micro-array tissue, immunoprecipitation, in situ hybridization and other are immune
Tissue chemical technology, radioimmunoassay, immunoradiometry and immunoenzymometric.
5. a kind of for monitoring the kit of Radiotherapy for Pituitary Adenoma sensibility or repellence, wherein the kit includes
The reagent of quantitative detection of molecules marker, the molecular marker be selected from EGFR, DRD2, SFRP2, MGMT, VCAM, FSCN,
At least one of P21, phosphorylation SMAD3 and phosphorylated CREB 1/2.
6. kit according to claim 5, wherein the molecular marker be EGFR, DRD2, SFRP2, MGMT,
VCAM, FSCN, P21, phosphorylation SMAD3 and phosphorylated CREB 1/2.
7. kit according to claim 5 or 6, wherein the reagent is PCR reagent, western blot, North-
Western blot, immmunosorbent assay, Antibody microarray, micro-array tissue, immunoprecipitation, in situ hybridization and other are immune
Tissue chemical technology, radioimmunoassay, immunoradiometry, immunoenzymometric detection reagent.
8. a kind of molecular marker for detecting Radiotherapy for Pituitary Adenoma sensibility or repellence combines, wherein the molecule
Marker combination includes in EGFR, DRD2, SFRP2, MGMT, VCAM, FSCN, P21, phosphorylation SMAD3 and phosphorylated CREB 1/2
At least two.
9. molecular marker according to claim 8 combination, wherein the molecular marker combination by EGFR, DRD2,
SFRP2, MGMT, VCAM, FSCN, P21, phosphorylation SMAD3 and phosphorylated CREB 1/2 form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710744118.9A CN109423516A (en) | 2017-08-25 | 2017-08-25 | Pass through the kit of molecular marker analyte detection Radiotherapy for Pituitary Adenoma sensibility or repellence |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710744118.9A CN109423516A (en) | 2017-08-25 | 2017-08-25 | Pass through the kit of molecular marker analyte detection Radiotherapy for Pituitary Adenoma sensibility or repellence |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN109423516A true CN109423516A (en) | 2019-03-05 |
Family
ID=65499540
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201710744118.9A Pending CN109423516A (en) | 2017-08-25 | 2017-08-25 | Pass through the kit of molecular marker analyte detection Radiotherapy for Pituitary Adenoma sensibility or repellence |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN109423516A (en) |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101283106A (en) * | 2005-07-27 | 2008-10-08 | 肿瘤疗法科学股份有限公司 | Method of diagnosing small cell lung cancer |
| CN102740888A (en) * | 2009-11-24 | 2012-10-17 | 奥尔德生物制药公司 | Antibodies to IL-6 and use there |
| WO2016141324A2 (en) * | 2015-03-05 | 2016-09-09 | Trovagene, Inc. | Early assessment of mechanism of action and efficacy of anti-cancer therapies using molecular markers in bodily fluids |
| CN106153921A (en) * | 2016-08-04 | 2016-11-23 | 北京市神经外科研究所 | Biomarker detectable purposes in the test kit of preparation detection Invasiveness of Pituitary Adenomas |
-
2017
- 2017-08-25 CN CN201710744118.9A patent/CN109423516A/en active Pending
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101283106A (en) * | 2005-07-27 | 2008-10-08 | 肿瘤疗法科学股份有限公司 | Method of diagnosing small cell lung cancer |
| CN102740888A (en) * | 2009-11-24 | 2012-10-17 | 奥尔德生物制药公司 | Antibodies to IL-6 and use there |
| WO2016141324A2 (en) * | 2015-03-05 | 2016-09-09 | Trovagene, Inc. | Early assessment of mechanism of action and efficacy of anti-cancer therapies using molecular markers in bodily fluids |
| CN106153921A (en) * | 2016-08-04 | 2016-11-23 | 北京市神经外科研究所 | Biomarker detectable purposes in the test kit of preparation detection Invasiveness of Pituitary Adenomas |
Non-Patent Citations (2)
| Title |
|---|
| ANN I. MCCORMACK等: "Aggressive pituitary tumours: the role of temozolomide and the assessment of MGMT status", 《EUROPEAN JOURNAL OF CLINICAL INVESTIGATION》 * |
| 裴亮等: "侵袭性垂体腺瘤治疗研究进展", 《临床军医杂志》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lee et al. | ER-α36, a novel variant of ER-α, is expressed in ER-positive and-negative human breast carcinomas | |
| Hsu et al. | Use of MIB-1 (Ki-67) immunoreactivity in differentiating grade II and grade III gliomas | |
| Williams et al. | Immunohistochemical detection of estrogen and progesterone receptor and HER2 expression in breast carcinomas: comparison of cell block and tissue block preparations | |
| McKeever et al. | MIB-1 proliferation index predicts survival among patients with grade II astrocytoma | |
| EP2062597A1 (en) | Preventive or remedy for er-negative and her2-negative breast cancer and method of screening the same | |
| Umemura et al. | Immunohistochemical evaluation for hormone receptors in breast cancer: a practically useful evaluation system and handling protocol | |
| CN103403550A (en) | Means and methods for diagnosing cancer using an antibody which specifically binds to BRAF V600E | |
| CN102516390B (en) | Preparation of multi-epitope TK-1 antibody, and application of multi-epitope TK-1 antibody in evaluating treatment effect on tumor patient | |
| CN107436356A (en) | The kit resisted by protein markers analyte detection Radiotherapy for Pituitary Adenoma | |
| Unger et al. | Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours | |
| Yu et al. | Clinical importance of somatostatin receptor 2 (SSTR2) and somatostatin receptor 5 (SSTR5) expression in thyrotropin-producing pituitary adenoma (TSHoma) | |
| EP1301794B1 (en) | Method for quantification of akt protein expression | |
| Alba et al. | HER2 status determination using RNA-ISH-a rapid and simple technique showing high correlation with FISH and IHC in 141 cases of breast cancer | |
| CN109423516A (en) | Pass through the kit of molecular marker analyte detection Radiotherapy for Pituitary Adenoma sensibility or repellence | |
| CN109541221B (en) | c-Met specific antibody, composition and kit | |
| Shukuwa et al. | Diethylstilbestrol increases the density of prolactin cells in male mouse pituitary by inducing proliferation of prolactin cells and transdifferentiation of gonadotropic cells | |
| CN107436357A (en) | A kind of kit by protein markers analyte detection Radiotherapy for Pituitary Adenoma sensitiveness | |
| CN107436355A (en) | Pass through the kit of protein markers analyte detection endocrine active pituitary adenoma radiation sensitivity | |
| CN102435734A (en) | Kit used for evaluating ovarian cancer primary chemotherapeutic sensitivity, and application thereof | |
| Ruan et al. | HER-2 status and its clinicopathologic significance in breast cancer in patients from southwest China: re-evaluation of correlation between results from FISH and IHC | |
| CN111024944B (en) | Kit for predicting pituitary adenoma radiotherapy sensitivity or resistance through molecular markers | |
| KR102028703B1 (en) | Biomarker for diagnosis and treatment of breast cancer | |
| CA2739171A1 (en) | Biomarker for microdomain diease | |
| CN105233290A (en) | C22orf26 gene and application of expression product of C22orf26 gene to preparing Parkinson diagnosis and treatment preparation | |
| CN112111575B (en) | Application of insulin-like growth factor 2 in prognosis and treatment selection of malignant tumor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190305 |
|
| WD01 | Invention patent application deemed withdrawn after publication |